ARS Pharmaceuticals
SPRY
ARS Pharmaceuticals (SPRY) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $24.00 from $25.00 | Jun 25, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 from $12.00 | May 28, 2026 |
| Roth Capital | Initiated Coverage | Buy | $40.00 | Sep 4, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $30.00 | Mar 7, 2025 |
| Raymond James | Maintained | Strong Buy | $28.00 from $26.00 | Jan 14, 2025 |
| Leerink Partners | Maintained | Outperform | $27.00 from $26.00 | Jan 13, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 | Oct 8, 2024 |
| Leerink Partners | Maintained | Outperform | $25.00 from $21.00 | Sep 20, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 | Sep 16, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 | Sep 9, 2024 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $30.00 | Aug 20, 2024 |
| Raymond James | Upgraded | Outperform → Strong Buy | $22.00 from $18.00 | Aug 13, 2024 |
| Raymond James | Initiated Coverage | Outperform | $18.00 | Jul 25, 2024 |
| Wedbush | Maintained | Outperform | $19.00 | Mar 11, 2024 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $18.00 from $6.00 | Mar 5, 2024 |
| Wedbush | Maintained | Outperform | $13.00 from $5.00 | Nov 13, 2023 |
| Wedbush | Maintained | Outperform | $5.00 from $15.00 | Sep 21, 2023 |
| William Blair | Downgraded | Outperform → Market Perform | — | Sep 20, 2023 |
| Wedbush | Maintained | Outperform | $15.00 | Aug 14, 2023 |
| Wedbush | Maintained | Outperform | $15.00 from $17.00 | Jun 21, 2023 |
Frequently asked questions
What is the latest analyst rating on SPRY?
On Jun 25, 2026, Leerink Partners maintained ARS Pharmaceuticals at Outperform with a price target of $24.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.